The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The HNO model recapitulates some key pathological features of AD and offers greater complexity and translational potential compared to conventional cell and animal models.
“The HNO model has been shown to recapitulate some of the key pathological features of AD and offers greater complexity and translational potential as compared to conventional cell and animal models92–95.”
From GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedCerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure
Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Organoids as an in vitro model of human development and disease
Fatehullah, A., Tan, S. H., & Barker, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3312 · Cited by 1,508
Cell diversity and network dynamics in photosensitive human brain organoids
Quadrato, G., Nguyen, T., Macosko, E. Z., Sherwood, J. L., Min Yang, S., Berger, D. R., Maria, N., Scholvin, J., Goldman, M., Kinney, J. P., et al. (2017) · Nature · doi:10.1038/nature22047 · Cited by 1,321
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
Epigenetic mechanisms of longevity and aging
Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016) · Cell · doi:10.1016/j.cell.2016.07.050 · Cited by 956
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Raja, W. K., Mungenast, A. E., Lin, Y.-T., Ko, T., Abdurrob, F., Seo, J., & Tsai, L.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161969 · Cited by 569
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532
Modeling amyloid beta and tau pathology in human cerebral organoids
Gonzalez, C., Armijo, E., Bravo-Alegria, J., Becerra-Calixto, A., Mays, C. E., & Soto, C. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0229-8 · Cited by 430
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Lessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178
Aging and reprogramming: a two-way street
Mahmoudi, S., & Brunet, A. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.10.004 · Cited by 171
Flagged first, then by citations
Research works printed but not linked: 28
- J. Cummings, 2018, Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes, Clin Transl Sci, 11, 147, 10.1111/cts.12491 · DOI · Paper page
- SE Cavanaugh, 2014, Animal models of Alzheimer disease: historical pitfalls and a path forward, ALTEX, 31, 279, 10.14573/altex.1310071 · DOI · Paper page
- LSB Goldstein, 2015, Probing the secrets of Alzheimer’s disease using human-induced pluripotent stem cell technology, Neurotherapeutics
- K Freude, 2014, Induced Pluripotent Stem Cells Derived from Alzheimer’s Disease Patients: The Promise, the Hope and the Path Ahead, J Clin Med, 3, 1402, 10.3390/jcm3041402 · DOI
- CJC Parr, 2017, An update on stem cell biology and engineering for brain development, Mol Psychiatry, 22, 808, 10.1038/mp.2017.66 · DOI
- CR Muratore, 2014, Comparison and optimization of hiPSC forebrain cortical differentiation protocols, PLoS One, 9, 1, 10.1371/journal.pone.0105807 · DOI
- C D’Avanzo, 2015, Alzheimer’s in 3D culture: Challenges and perspectives, BioEssays
- KJ Brennand, 2015, Creating Patient-Specific Neural Cells for the in Vitro Study of Brain Disorders, Stem Cell Reports, 5, 933, 10.1016/j.stemcr.2015.10.011 · DOI
- D Hirtz, 2007, How common are the “common” neurologic disorders?, Neurology, 68, 326, 10.1212/01.wnl.0000252807.38124.a3 · DOI · Paper page
- JA Hardy, 1992, Alzheimer’s Disease: The Amyloid Cascade Hypotesis, Science, 256, 184, 10.1126/science.1566067 · DOI · Paper page
- RE Tanzi, 2005, Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008 · DOI · Paper page
- A Hochard, 2013, Aftins Increase Amyloid-β42, Lower Amyloid-β38, and Do Not Alter Amyloid-β40 Extracellular Production in vitro: Toward a Chemical Model of Alzheimer’s Disease?, J Alzheimer’s Dis, 35, 107, 10.3233/JAD-121777 · DOI
- MA Lancaster, 2014, Generation of cerebral organoids from human pluripotent stem cells, Nat Protoc, 9, 2329, 10.1038/nprot.2014.158 · DOI · Paper page
- AT Brawner, 2017, Generating CNS organoids from human induced pluripotent stem cells for modeling neurological disorders, Int J Physiol Pathophysiol Pharmacol, 9, 101
- LT Ghaffari, 2018, Representing Diversity in the Dish: Using Patient-Derived in Vitro Models to Recreate the Heterogeneity of Neurological Disease, Front Neurosci, 12, 10.3389/fnins.2018.00056 · DOI
- P Lewczuk, 2017, Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease, J Alzheimer’s Dis, 55, 813, 10.3233/JAD-160722 · DOI · Paper page
- LE Collins-Praino, 2014, Soluble amyloid beta levels are elevated in the white matter of Alzheimer’s patients, independent of cortical plaque severity, Acta Neuropathol Commun, 2, 83
- L Lue, 1999, Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease, Am J Pathol, 155, 853, 10.1016/S0002-9440(10)65184-X · DOI · Paper page
- PE Spies, 2010, The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia, Curr Alzheimer Res., 7, 470, 10.2174/156720510791383796 · DOI
- PP Shah, 2013, Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape, Genes Dev
- M Goedert, 2015, Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein, Science, 349, 601, 10.1126/science.1255555 · DOI
- E Gunther, 2010, β-amyloid oligomers and cellular prion protein in Alzheimer’s disease, J Mol Med, 88, 331, 10.1007/s00109-009-0568-7 · DOI
- WQ Zou, 2011, Amyloid-β42 interacts mainly with insoluble prion protein in the Alzheimer brain, J Biol Chem, 286, 15095, 10.1074/jbc.M110.199356 · DOI
- J Manson, 1992, The prion protein gene: a role in mouse embryogenesis?, Development, 115, 117, 10.1242/dev.115.1.117 · DOI
- GG Kovacs, 2002, The prion protein in human neurodegenerative disorders, Neurosci Lett, 329, 269, 10.1016/S0304-3940(02)00668-7 · DOI
- H Adle-Biassette, 2006, Immunohistochemical Expression of Prion Protein (PrPC) in the Human Forebrain During Development, J Neuropathol Exp Neurol, 65, 698, 10.1097/01.jnen.0000228137.10531.72 · DOI
- AD Steele, 2006, Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis, Proc Natl Acad Sci, 103, 3416, 10.1073/pnas.0511290103 · DOI
- SD Sheridan, 2012, Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency, Stem Cells Int
Cited by
Sorted by citations
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau
Acosta Ingram, D., Turkes, E., Kim, T. Y., Vo, S., Sweeney, N., Bonte, M.-A., Rutherford, R., Julian, D. L., Pan, M., Marsh, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58585-w · Cited by 12
Metadata
- Authors
- Pavoni, S., Jarray, R., Nassor, F., Guyot, A.-C., Cottin, S., Rontard, J., Mikol, J., Mabondzo, A., Deslys, J.-P., & Yates, F.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-12-17
- Volume
- 13
- Issue
- 12
- Pages
- e0209150
- ISSN
- 1932-6203
- PMC
- PMC6296660
- Cited by
- 97
- References
- 18
- Language
- en
- Funders
- JPND (3DMiniBrain)
- Plan Investissement d'Avenir (PIA2) (P112331-3422142-3DNeuroSecure)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
